One of the world’s biggest pharmaceutical companies,Pfizer Inc. (NYSE:PFE) has witnessed an insider selling the company’s shares recently. This comes on the heels of the drug maker aborting its bid to acquire Britain-based healthcare company AstraZeneca plc (ADR) (NYSE:AZN) and its decision to settle the Neurontin drug issue for the alleged unapproved usage of the drug. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is -1.21%. On last trading day company shares ended up $29.35. Analysts mean target price for the company is $34.55. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average is -2.71%.
Bristol-Myers Squibb Company (NYSE:BMY) announced that Giovanni Caforio, M.D., has been appointed chief operating officer and elected to Bristol-Myers Squibb’s Board of Directors, effective June 5, 2014. He will continue to report to Lamberto Andreotti, chief executive officer. In addition to his current responsibilities as chief commercial officer, Caforio will add leadership responsibility for the company-wide functions of Enterprise Services and Global Manufacturing & Supply. Bristol-Myers Squibb Co (NYSE:BMY) shares fell -1.40% in last trading session and ended the day on $46.59. BMY Gross Margin is 72.40% and its return on assets is 8.00%. Bristol-Myers Squibb Co (NYSE:BMY) quarterly performance is -16.43%.
Merck & Co., Inc. (NYSE:MRK) said Monday it would buy Idenix Pharmaceuticals Inc IDIX.O for $3.85 billion and plans to combine the two companies’ most promising drugs to produce a faster, more effective cure for hepatitis C. Merck & Co., Inc. (NYSE:MRK) shares moved up 0.16% in last trading session and was closed at $57.94, while trading in range of $57.24-$57.97. Merck & Co., Inc. (NYSE:MRK) year to date performance is 16.67%.
Lawsuits filed against Abbott Laboratories and its spinoff company AbbVie Inc (NYSE:ABBV) over the risks they supposedly hid of using the testosterone-replacement drug AndroGel has been combined in one Chicago court. This has been confirmed by a panel of judges yesterday in its decision to consolidate the cases lodged against the two companies.
AbbVie Inc (NYSE:ABBV) ended the last trading day at $53.84. Company weekly volatility is calculated as 1.56% and price to cash ratio as 9.41. AbbVie Inc (NYSE:ABBV) showed a negative weekly performance of -0.57%.
Stock analysts at R. F. Lafferty initiated coverage on shares of Zogenix (NASDAQ:ZGNX) in a report issued on Friday. The firm set a “buy” rating and a $3.50 price target on the stock. Zogenix, Inc. (NASDAQ:ZGNX) weekly performance is -11.54%. On last trading day company shares ended up $1.84. Analysts mean target price for the company is $4.73. Zogenix, Inc. (NASDAQ:ZGNX) distance from 50-day simple moving average is -23.94%.